Compare · ABBV vs INSM
ABBV vs INSM
Side-by-side comparison of AbbVie Inc. (ABBV) and Insmed Incorporated (INSM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and INSM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $401.47B, about 19.7x INSM ($20.42B).
- Over the past year, ABBV is up 17.8% and INSM is up 34.6% - INSM leads by 16.8 points.
- ABBV has been more active in the news (10 items in the past 4 weeks vs 9 for INSM).
- Both have 25 recent analyst ratings on file.
- Company
- AbbVie Inc.
- Insmed Incorporated
- Price
- $222.73-1.92%
- $95.11+1.01%
- Market cap
- $401.47B
- $20.42B
- 1M return
- +9.91%
- -9.24%
- 1Y return
- +17.82%
- +34.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 10
- 9
- Recent ratings
- 25
- 25
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Latest ABBV
- AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
Latest INSM
- Chief Operating Officer Adsett Roger sold $242,380 worth of shares (2,370 units at $102.27), decreasing direct ownership by 2% to 98,603 units (SEC Form 4) (tax liability)
- Chief Financial Officer Bonstein Sara sold $245,857 worth of shares (2,404 units at $102.27), decreasing direct ownership by 3% to 69,082 units (SEC Form 4) (tax withholding)
- Chief Legal Officer Smith Michael Alexander sold $220,801 worth of shares (2,159 units at $102.27), decreasing direct ownership by 5% to 39,454 units (SEC Form 4) (tax liability)
- Chief Medical Officer Flammer Martina M.D. sold $455,248 worth of shares (4,424 units at $102.90) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 60,486 units (SEC Form 4) to satisfy withholding obligation
- Chair and CEO Lewis William sold $777,763 worth of shares (7,605 units at $102.27), decreasing direct ownership by 3% to 265,432 units (SEC Form 4) (for tax liability)
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
- Chief Legal Officer Smith Michael Alexander sold $666,982 worth of shares (6,149 units at $108.47) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 41,613 units (SEC Form 4)
- Chair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $2,718,224 worth of shares (25,564 units at $106.33) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 273,037 units (SEC Form 4)
- SEC Form S-3ASR filed by Insmed Incorporated